Stock 1C0S CELYAD ONCOLOGY SA
Add to a list
To use this feature you must be a member
Log inSign up

Celyad Oncology SA Stock BOERSE MUENCHEN

Equities

1C0S

US1512052002

Biotechnology & Medical Research

Real-time BOERSE MUENCHEN
Other stock markets
 		5-day change 1st Jan Change
- EUR -.--% Intraday chart for Celyad Oncology SA +10.27% -.--%
04-04 Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
02-09 Celyad Oncology Seeks Termination of Reporting Obligations to US SEC MT

Financials

Sales 2022 - Sales 2023 102K 109K 149K Capitalization 16.16M 17.3M 23.67M
Net income 2022 -40M -42.82M -58.59M Net income 2023 -8M -8.56M -11.72M EV / Sales 2022 -
Net cash position 2022 12.19M 13.05M 17.86M Net cash position 2023 5.95M 6.37M 8.71M EV / Sales 2023 100 x
P/E ratio 2022
-0.28 x
P/E ratio 2023
-1.19 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 92.37%
More Fundamentals * Assessed data

Chart Celyad Oncology SA

Dynamic Chart

Latest news about Celyad Oncology SA

Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Celyad Oncology Seeks Termination of Reporting Obligations to US SEC MT
Celyad Oncology CEO Resigns MT
Celyad Oncology CEO Steps Down for Personal Reasons MT
Celyad Oncology SA Announces Executive Change CI
Celyad Oncology Sa Announces Executive Change CI
Celyad Oncology SA announced that it has received ?9.794 million in funding from CFIP CLYD (UK) Limited, Fortress Investment Group LLC, Tolefi S.A. CI
Celyad Oncology to Cancel American Depository Receipt Program in October MT
Transcript : Celyad Oncology SA, H1 2023 Earnings Call, Sep 05, 2023
Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Celyad Oncology Secures EUR10 Million via Private Placement With Historical Investors MT
Celyad Oncology SA announced that it expects to receive ?9.794 million in funding from Fortress Investment Group LLC, Tolefi S.A., and other investors CI
Celyad Oncology SA(OTCUS:CYAD.Y) dropped from NASDAQ Composite Index CI
Global markets live: Boohoo, KBC, Vodafone, Home Depot, Ford... Our Logo
Celyad Oncology's American Depositary Shares to Be Delisted from Nasdaq MT
More news

Latest transcript on Celyad Oncology SA

Logo Celyad Oncology SA
Celyad Oncology SA, H1 2023 Earnings Call, Sep 05, 2023
More transcripts

Analyst Recommendations on Celyad Oncology SA

HC Wainwright Downgrades Celyad Oncology Neutral From Buy, Shares Plunge 12% at Midday Trading MT
Wells Fargo Adjusts Celyad Oncology's Price Target to $11 from $20, Keeps Overweight Rating MT
Wall Street Set for Narrow Gains, US Unemployment Rate Falls in November MT
CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Maintains Buy Rating MT
CELYAD ONCOLOGY : JonesTrading Downgrades Celyad Oncology to Hold from Buy MT
More recommendations

Press releases Celyad Oncology SA

Celyad Oncology reports full year 2023 financial results and recent business highlights AQ
Celyad Oncology : Report of the Statutory Auditor on the Consolidated Annual Account 2023 ENG PU
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook AQ
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007) AQ
Celyad announces management change AQ
More press releases

News in other languages on Celyad Oncology SA

Celyad Oncology : Rapport Annuel 2023 FR
Celyad Oncology : Statuts - version informelle FR
Celyad Oncology : Report of the Statutory Auditor on the Statutory Annual Account 2023 FR
Celyad Oncology : Report of the Statutory Auditor on the Consolidated Annual Account 2023 FR
Celyad Oncology: 7 millions d'euros de trésorerie, visibilité jusqu'au 2e trimestre 2025
More news

Managers and Directors - Celyad Oncology SA

Managers TitleAgeSince
Michel Lussier FOU
 Founder 67 07-07-23
David Georges DFI
 Director of Finance/CFO - 18-12-31
Eytan Breman CTO
 Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Michel Lussier FOU
 Founder 67 07-07-23
Hilde Windels CHM
 Chairman 59 18-05-06
Serge Goblet BRD
 Director/Board Member - 07-12-31
More insiders

Company Profile

Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Sector
Biotechnology & Medical Research
Calendar
2024-09-20 - Q2 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+21.39% 46.93B
LONZA GROUP AG Stock Lonza Group AG
+37.63% 39.08B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.43% 38.48B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.07% 31.01B
CELLTRION, INC. Stock Celltrion, Inc.
-13.75% 26.14B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.14% 25.88B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+36.17% 12.53B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-6.69% 11.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.47% 10.65B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CYAD Stock
  4. 1C0S Stock